MVR-C5252

DB30379InvestigationalGene Therapies

MVR-C5252 is a biologic drug. MVR-C5252 is under investigation in clinical trial NCT06126744 (Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of the Oncolytic HSV1 MVR-C5252).

Mechanism: Pharmacologically active on Programmed cell death protein 1
Curator reviewed
Also known as: C5252
Code names: MVR-C5252

Resolves to

Targets

Q15116PDCD1

What you can answer from here — as of June 20, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with MVR-C5252, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account